Mylan NV (MYL)

16.11
0.43 2.60
NASDAQ : Health Technology
Prev Close 16.54
Open 16.33
Day Low/High 15.95 / 16.55
52 Wk Low/High 12.75 / 23.11
Volume 5.48M
Avg Volume 6.46M
Exchange NASDAQ
Shares Outstanding 516.95M
Market Cap 8.23B
P/E Ratio 132.75
Div & Yield N.A. (N.A)
5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

IEA Sharply Cuts Global Growth Projections for Oil, Blames Demand in Asia

IEA Sharply Cuts Global Growth Projections for Oil, Blames Demand in Asia

The International Energy Agency says 'wobbly' demand in Asia will lead to a longer rebalancing of the oil market than originally thought.

Cramer: We Need to Be Able to Predict a Clear Election Winner

Cramer: We Need to Be Able to Predict a Clear Election Winner

Without it, the uncertainty would be incredible between now and November.

Perrigo Shares Climb on Starboard Value Investment

Perrigo Shares Climb on Starboard Value Investment

The activist fund says Perrigo's promises over the past year have been "woefully unfulfilled."

Morning Movers: PRGO, MYL, HPQ, MRO, RIG

Morning Movers: PRGO, MYL, HPQ, MRO, RIG

Falling crude oil prices continued to weigh on markets Monday.

Mylan Still Isn't Cheap

Mylan Still Isn't Cheap

The EpiPen controversy makes this stock a shot in the dark.

Mylan estimates, target cut at RBC

Trending Tickers: MYL, MNK, VRX, CHK, UA

Trending Tickers: MYL, MNK, VRX, CHK, UA

Rising oil prices helped buoy U.S. markets Friday.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

S&P 500 Poised to Shake Off Summer Doldrums

S&P 500 Poised to Shake Off Summer Doldrums

Jobs and GDP reports plus a possible rate hike are setting up the market for big moves.

2 Biotechs to Watch Ahead of the Election

2 Biotechs to Watch Ahead of the Election

These 2 small-caps have strong pipelines and are becoming analyst darlings.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

5 Winning Stocks That Could Be Ready to Drop

5 Winning Stocks That Could Be Ready to Drop

Past price action does not guarantee future price action.

Mylan Lowers Prices on EpiPens But Jim Cramer Still Doesn't Like the Stock

Mylan Lowers Prices on EpiPens But Jim Cramer Still Doesn't Like the Stock

Mylan seeks to quell public outrage of its EpiPen Pricing with a generic version of the product.

Mylan Shares Jump on Discounted EpiPen Offering

Mylan Shares Jump on Discounted EpiPen Offering

The drugmaker's shares are higher after announcing the discounted allergy treatment.

U.S. Stocks Rise as Investors Weigh September Rate Hike; Mylan to Offer Generic EpiPen

U.S. Stocks Rise as Investors Weigh September Rate Hike; Mylan to Offer Generic EpiPen

U.S. stocks are higher Monday, as investors continued to digest comments on interest rates from Federal Reserve Chair Janet Yellen on Friday.

Morning Movers: HLF, MYL, WLL, HOG

Morning Movers: HLF, MYL, WLL, HOG

Herbalife shares were climbing after Carl Icahn heated up his long-running spat with Bill Ackman.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Trader's Daily Notebook: Is It Worth Trying to Catch a Bottom in Biotechs?

Trader's Daily Notebook: Is It Worth Trying to Catch a Bottom in Biotechs?

The recent harsh spotlight on the sector raises the question.

As Predictable As the Sun Rising

Some things are just so predictable: The business media will inundate us with hours of "analysis" of Mylan this week. Yet, though time-consumptive, the dialogue on Mylan will not likely be particularly revealing. (Thirty minutes would have sufficed)...

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

More competition in the drug industry would prevent situations like the big price hike in Mylan's EpiPens, according to Jim Cramer.

Cramer: Getting to the Heart -- or the Lack of It -- of the EpiPen Issue

Cramer: Getting to the Heart -- or the Lack of It -- of the EpiPen Issue

Competition could be the cure, not demonizing the drugmaker's CEO.

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

After Mylan raised the price of its EpiPen by 400 percent, sparking a wave of controversy, the company now saying it will offer a savings card worth $300 to users.

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. stocks moved slightly lower on Thursday as investors anxiously await remarks from Federal Reserve Chair Janet Yellen on Friday.

Mylan EpiPen Controversy Puts More Biotechs in Danger

Mylan EpiPen Controversy Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

Mylan Dispute Puts More Biotechs in Danger

Mylan Dispute Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

Mallinckrodt's Top Drug Could Go the Way of EpiPen

Mallinckrodt's Top Drug Could Go the Way of EpiPen

The drug that's helping boost the company's stock could become its biggest risk.

Morning Movers: SHLD, TIF, DG, DLTR, MYL

Morning Movers: SHLD, TIF, DG, DLTR, MYL

The discount dollar stores quarterly results disappoint, while Tiffany beats profit forecasts.

Rev's Forum: Market Resets, Waiting for Janet Yellen

Rev's Forum: Market Resets, Waiting for Janet Yellen

The indexes' positive tone shifted in the last two days.

Cramer: The Stock Market Is Helping the Consumer This Year

Cramer: The Stock Market Is Helping the Consumer This Year

It could well be the stock market, not the Fed, that is driving our retail and services.